Iceland· IS-EU/1/21/1613/001-004
Lyfnua
A gefapixant product containing gefapixantum inn, registered in Iceland by Merck Sharp & Dohme B.V.*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Gefapixant is registered in 13 of 19 countries.
Countries holding a registration under ATC R05DB29 (gefapixant), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Gefapixant · ATC R05DB29
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Gefapixantum INN
- Manufacturer
- Merck Sharp & Dohme B.V.*
- Country
- Iceland (IS)
- ATC code
- R05DB29
- ATC class
- Gefapixant
- Defined daily dose
- 90 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean96804856 stk x1 pakkiISK 24551
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Gefapixant in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLYFNUAMerck Sharp & Dohme B.V., Haarlem
- SpainLYFNUA 45 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- FinlandLyfnuaMerck Sharp & Dohme B.V.
- FranceLYFNUA 45 mg, comprimé pelliculéMERCK SHARP & DOHME (PAYS-BAS)
- IrelandLYFNUA 45 mg Film-coated tabletMerck Sharp & Dohme BV,
- NetherlandsLyfnua 45 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
- NorwayLyfnuaMerck Sharp & Dohme B.V.
- PolandLyfnuaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Lyfnua
- Norway · Lyfnua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/927660a6-0f2c-42ae-a28d-7595490da02e GET /v1/drugs/927660a6-0f2c-42ae-a28d-7595490da02e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "R05DB29",
"marketed": true,
"strength": "45 mg",
"ma_number": "EU/1/21/1613/001-004",
"substance": "Gefapixantum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "45184"
}See everything about gefapixant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.